<?xml version="1.0" encoding="UTF-8"?>
<html lang="en" dir="ltr" xmlns="http://www.w3.org/1999/xhtml">
 <head prefix="og: http://ogp.me/ns# article: http://ogp.me/ns/article# book: http://ogp.me/ns/book#"> 
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/> 
  <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=3, minimum-scale=1, user-scalable=yes"/> 
  <meta name="type" content="article"/>
  <meta name="HW.identifier" content="/biorxiv/early/2020/04/13/2020.04.08.026948.atom"/>
  <meta name="HW.pisa" content="biorxiv;2020.04.08.026948v2"/>
  <meta name="DC.Format" content="text/html"/>
  <meta name="DC.Language" content="en"/>
  <meta name="DC.Title" content="Robust neutralization assay based on SARS-CoV-2 S-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressed BHK21 cells"/>
  <meta name="DC.Identifier" content="10.1101/2020.04.08.026948"/>
  <meta name="DC.Date" content="2020-04-13"/>
  <meta name="DC.Publisher" content="Cold Spring Harbor Laboratory"/>
  <meta name="DC.Rights" content="Â© 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/"/>
  <meta name="DC.AccessRights" content="restricted"/>
  <meta name="DC.Description" content="The global pandemic of Coronavirus disease 2019 (COVID-19) is a disaster for human society. A convenient and reliable in vitro neutralization assay is very important for the development of neutralizing antibodies, vaccines and other inhibitors. In this study, G protein-deficient vesicular stomatitis virus (VSVdG) bearing full-length and truncated spike (S) protein of SARS-CoV-2 were evaluated. The virus packaging efficiency of VSV-SARS-CoV-2-Sdel18 (S with C-terminal 18 amino acid truncation) is much higher than VSV-SARS-CoV-2-S. A neutralization assay for antibody screening and serum neutralizing titer quantification was established based on VSV-SARS-CoV-2-Sdel18 pseudovirus and human angiotensin-converting enzyme 2 (ACE2) overexpressed BHK21 cell (BHK21-hACE2). The experimental results can be obtained by automatically counting EGFP positive cell number at 12 hours after infection, making the assay convenient and high-throughput. The serum neutralizing titer of COVID-19 convalescent patients measured by VSV-SARS-CoV-2-Sdel18 pseudovirus assay has a good correlation with live SARS-CoV-2 assay. Seven neutralizing monoclonal antibodies targeting receptor binding domain (RBD) of SARS-CoV-2-S were obtained. This efficient and reliable pseudovirus assay model could facilitate the development of new drugs and vaccines. ### Competing Interest Statement The authors have declared no competing interest."/>
  <meta name="DC.Contributor" content="Hualong Xiong"/>
  <meta name="DC.Contributor" content="Yangtao Wu"/>
  <meta name="DC.Contributor" content="Jiali Cao"/>
  <meta name="DC.Contributor" content="Ren Yang"/>
  <meta name="DC.Contributor" content="Jian Ma"/>
  <meta name="DC.Contributor" content="Xiaoyang Qiao"/>
  <meta name="DC.Contributor" content="Xiangyang Yao"/>
  <meta name="DC.Contributor" content="Baohui Zhang"/>
  <meta name="DC.Contributor" content="Yali Zhang"/>
  <meta name="DC.Contributor" content="Wangheng Hou"/>
  <meta name="DC.Contributor" content="Yang Shi"/>
  <meta name="DC.Contributor" content="Jingjing Xu"/>
  <meta name="DC.Contributor" content="Liang Zhang"/>
  <meta name="DC.Contributor" content="Shaojuan Wang"/>
  <meta name="DC.Contributor" content="Baorong Fu"/>
  <meta name="DC.Contributor" content="Ting Yang"/>
  <meta name="DC.Contributor" content="Shengxiang Ge"/>
  <meta name="DC.Contributor" content="Jun Zhang"/>
  <meta name="DC.Contributor" content="Quan Yuan"/>
  <meta name="DC.Contributor" content="Baoying Huang"/>
  <meta name="DC.Contributor" content="Zhiyong Li"/>
  <meta name="DC.Contributor" content="Tianying Zhang"/>
  <meta name="DC.Contributor" content="Ningshao Xia"/>
  <meta name="article:published_time" content="2020-04-13"/>
  <meta name="article:section" content="New Results"/>
  <meta name="citation_title" content="Robust neutralization assay based on SARS-CoV-2 S-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressed BHK21 cells"/>
  <meta name="citation_abstract" lang="en" content="&lt;;p&gt;;The global pandemic of Coronavirus disease 2019 (COVID-19) is a disaster for human society. A convenient and reliable in vitro neutralization assay is very important for the development of neutralizing antibodies, vaccines and other inhibitors. In this study, G protein-deficient vesicular stomatitis virus (VSVdG) bearing full-length and truncated spike (S) protein of SARS-CoV-2 were evaluated. The virus packaging efficiency of VSV-SARS-CoV-2-Sdel18 (S with C-terminal 18 amino acid truncation) is much higher than VSV-SARS-CoV-2-S. A neutralization assay for antibody screening and serum neutralizing titer quantification was established based on VSV-SARS-CoV-2-Sdel18 pseudovirus and human angiotensin-converting enzyme 2 (ACE2) overexpressed BHK21 cell (BHK21-hACE2). The experimental results can be obtained by automatically counting EGFP positive cell number at 12 hours after infection, making the assay convenient and high-throughput. The serum neutralizing titer of COVID-19 convalescent patients measured by VSV-SARS-CoV-2-Sdel18 pseudovirus assay has a good correlation with live SARS-CoV-2 assay. Seven neutralizing monoclonal antibodies targeting receptor binding domain (RBD) of SARS-CoV-2-S were obtained. This efficient and reliable pseudovirus assay model could facilitate the development of new drugs and vaccines.&lt;;/p&gt;;"/>
  <meta name="citation_journal_title" content="bioRxiv"/>
  <meta name="citation_publisher" content="Cold Spring Harbor Laboratory"/>
  <meta name="citation_publication_date" content="2020/01/01"/>
  <meta name="citation_mjid" content="biorxiv;2020.04.08.026948v2"/>
  <meta name="citation_id" content="2020.04.08.026948v2"/>
  <meta name="citation_public_url" content="https://www.biorxiv.org/content/10.1101/2020.04.08.026948v2"/>
  <meta name="citation_abstract_html_url" content="https://www.biorxiv.org/content/10.1101/2020.04.08.026948v2.abstract"/>
  <meta name="citation_full_html_url" content="https://www.biorxiv.org/content/10.1101/2020.04.08.026948v2.full"/>
  <meta name="citation_pdf_url" content="https://www.biorxiv.org/content/biorxiv/early/2020/04/13/2020.04.08.026948.full.pdf"/>
  <meta name="citation_doi" content="10.1101/2020.04.08.026948"/>
  <meta name="citation_section" content="New Results"/>
  <meta name="citation_firstpage" content="2020.04.08.026948"/>
  <meta name="citation_author" content="Hualong Xiong"/>
  <meta name="citation_author_institution" content="Xiamen University;"/>
  <meta name="citation_author_email" content="hualxiong@163.com"/>
  <meta name="citation_author" content="Yangtao Wu"/>
  <meta name="citation_author_institution" content="Xiamen University;"/>
  <meta name="citation_author_email" content="yangtaowu_123@163.com"/>
  <meta name="citation_author" content="Jiali Cao"/>
  <meta name="citation_author_institution" content="Xiamen University;"/>
  <meta name="citation_author_email" content="21620141152524@stu.xmu.edu.cn"/>
  <meta name="citation_author" content="Ren Yang"/>
  <meta name="citation_author_institution" content="China CDC;"/>
  <meta name="citation_author" content="Jian Ma"/>
  <meta name="citation_author_institution" content="Xiamen University;"/>
  <meta name="citation_author_email" content="majian0153922@163.com"/>
  <meta name="citation_author" content="Xiaoyang Qiao"/>
  <meta name="citation_author_institution" content="Xiamen University;"/>
  <meta name="citation_author_email" content="can1239305749@foxmail.com"/>
  <meta name="citation_author" content="Xiangyang Yao"/>
  <meta name="citation_author_institution" content="The First Hospital of Xiamen University;"/>
  <meta name="citation_author" content="Baohui Zhang"/>
  <meta name="citation_author_institution" content="Xiamen University;"/>
  <meta name="citation_author" content="Yali Zhang"/>
  <meta name="citation_author_institution" content="Xiamen University;"/>
  <meta name="citation_author" content="Wangheng Hou"/>
  <meta name="citation_author_institution" content="Xiamen University;"/>
  <meta name="citation_author" content="Yang Shi"/>
  <meta name="citation_author_institution" content="Xiamen University;"/>
  <meta name="citation_author" content="Jingjing Xu"/>
  <meta name="citation_author_institution" content="Fujian Institute of Hematology"/>
  <meta name="citation_author" content="Liang Zhang"/>
  <meta name="citation_author_institution" content="Xiamen University;"/>
  <meta name="citation_author" content="Shaojuan Wang"/>
  <meta name="citation_author_institution" content="Xiamen University;"/>
  <meta name="citation_author" content="Baorong Fu"/>
  <meta name="citation_author_institution" content="Xiamen University;"/>
  <meta name="citation_author" content="Ting Yang"/>
  <meta name="citation_author_institution" content="Fujian Institute of Hematology"/>
  <meta name="citation_author" content="Shengxiang Ge"/>
  <meta name="citation_author_institution" content="Xiamen University;"/>
  <meta name="citation_author" content="Jun Zhang"/>
  <meta name="citation_author_institution" content="Xiamen University;"/>
  <meta name="citation_author" content="Quan Yuan"/>
  <meta name="citation_author_institution" content="Xiamen University;"/>
  <meta name="citation_author" content="Baoying Huang"/>
  <meta name="citation_author_institution" content="China CDC;"/>
  <meta name="citation_author_email" content="huangby@ivdc.chinacdc.cn"/>
  <meta name="citation_author" content="Zhiyong Li"/>
  <meta name="citation_author_institution" content="The First Hospital of Xiamen University;"/>
  <meta name="citation_author_email" content="xmlzy_213@163.com"/>
  <meta name="citation_author" content="Tianying Zhang"/>
  <meta name="citation_author_institution" content="Xiamen University;"/>
  <meta name="citation_author_email" content="tyzhang1003@163.com"/>
  <meta name="citation_author" content="Ningshao Xia"/>
  <meta name="citation_author_institution" content="Xiamen University;"/>
  <meta name="citation_author_email" content="nsxia@xmu.edu.cn"/>
  <meta name="citation_author_orcid" content="http://orcid.org/0000-0003-0179-5266"/>
  <meta name="twitter:title" content="Robust neutralization assay based on SARS-CoV-2 S-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressed BHK21 cells"/>
  <meta name="twitter:site" content="@biorxivpreprint"/>
  <meta name="twitter:card" content="summary"/>
  <meta name="twitter:image" content="https://www.biorxiv.org/sites/default/files/images/biorxiv_logo_homepage7-5-small.png"/>
  <meta name="twitter:description" content="The global pandemic of Coronavirus disease 2019 (COVID-19) is a disaster for human society. A convenient and reliable in vitro neutralization assay is very important for the development of neutralizing antibodies, vaccines and other inhibitors. In this study, G protein-deficient vesicular stomatitis virus (VSVdG) bearing full-length and truncated spike (S) protein of SARS-CoV-2 were evaluated. The virus packaging efficiency of VSV-SARS-CoV-2-Sdel18 (S with C-terminal 18 amino acid truncation) is much higher than VSV-SARS-CoV-2-S. A neutralization assay for antibody screening and serum neutralizing titer quantification was established based on VSV-SARS-CoV-2-Sdel18 pseudovirus and human angiotensin-converting enzyme 2 (ACE2) overexpressed BHK21 cell (BHK21-hACE2). The experimental results can be obtained by automatically counting EGFP positive cell number at 12 hours after infection, making the assay convenient and high-throughput. The serum neutralizing titer of COVID-19 convalescent patients measured by VSV-SARS-CoV-2-Sdel18 pseudovirus assay has a good correlation with live SARS-CoV-2 assay. Seven neutralizing monoclonal antibodies targeting receptor binding domain (RBD) of SARS-CoV-2-S were obtained. This efficient and reliable pseudovirus assay model could facilitate the development of new drugs and vaccines. ### Competing Interest Statement The authors have declared no competing interest."/>
  <meta name="og-title" property="og:title" content="Robust neutralization assay based on SARS-CoV-2 S-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressed BHK21 cells"/>
  <meta name="og-url" property="og:url" content="https://www.biorxiv.org/content/10.1101/2020.04.08.026948v2"/>
  <meta name="og-site-name" property="og:site_name" content="bioRxiv"/>
  <meta name="og-description" property="og:description" content="The global pandemic of Coronavirus disease 2019 (COVID-19) is a disaster for human society. A convenient and reliable in vitro neutralization assay is very important for the development of neutralizing antibodies, vaccines and other inhibitors. In this study, G protein-deficient vesicular stomatitis virus (VSVdG) bearing full-length and truncated spike (S) protein of SARS-CoV-2 were evaluated. The virus packaging efficiency of VSV-SARS-CoV-2-Sdel18 (S with C-terminal 18 amino acid truncation) is much higher than VSV-SARS-CoV-2-S. A neutralization assay for antibody screening and serum neutralizing titer quantification was established based on VSV-SARS-CoV-2-Sdel18 pseudovirus and human angiotensin-converting enzyme 2 (ACE2) overexpressed BHK21 cell (BHK21-hACE2). The experimental results can be obtained by automatically counting EGFP positive cell number at 12 hours after infection, making the assay convenient and high-throughput. The serum neutralizing titer of COVID-19 convalescent patients measured by VSV-SARS-CoV-2-Sdel18 pseudovirus assay has a good correlation with live SARS-CoV-2 assay. Seven neutralizing monoclonal antibodies targeting receptor binding domain (RBD) of SARS-CoV-2-S were obtained. This efficient and reliable pseudovirus assay model could facilitate the development of new drugs and vaccines. ### Competing Interest Statement The authors have declared no competing interest."/>
  <meta name="og-type" property="og:type" content="article"/>
  <meta name="og-image" property="og:image" content="https://www.biorxiv.org/sites/default/files/images/biorxiv_logo_homepage7-5-small.png"/>
  <meta name="citation_date" content="2020-04-13"/> 
  <meta name="description" content="bioRxiv - the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution"/>
  <meta name="generator" content="Drupal 7 (http://drupal.org)"/> 
  <title>Robust neutralization assay based on SARS-CoV-2 S-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressed BHK21 cells | bioRxiv</title> 
 </head>
 <body class="html not-front not-logged-in page-node page-node- page-node-1243820 node-type-highwire-article context-content hw-default-jcode-biorxiv hw-article-category-new-results"> 
  <div class="article abstract-view ">
   <span class="highwire-journal-article-marker-start"/>
   <div class="section abstract" id="abstract-1">
    <h2>Abstract</h2>
    <p id="p-2">The global pandemic of Coronavirus disease 2019 (COVID-19) is a disaster for human society. A convenient and reliable in vitro neutralization assay is very important for the development of neutralizing antibodies, vaccines and other inhibitors. In this study, G protein-deficient vesicular stomatitis virus (VSVdG) bearing full-length and truncated spike (S) protein of SARS-CoV-2 were evaluated. The virus packaging efficiency of VSV-SARS-CoV-2-Sdel18 (S with C-terminal 18 amino acid truncation) is much higher than VSV-SARS-CoV-2-S. A neutralization assay for antibody screening and serum neutralizing titer quantification was established based on VSV-SARS-CoV-2-Sdel18 pseudovirus and human angiotensin-converting enzyme 2 (ACE2) overexpressed BHK21 cell (BHK21-hACE2). The experimental results can be obtained by automatically counting EGFP positive cell number at 12 hours after infection, making the assay convenient and high-throughput. The serum neutralizing titer of COVID-19 convalescent patients measured by VSV-SARS-CoV-2-Sdel18 pseudovirus assay has a good correlation with live SARS-CoV-2 assay. Seven neutralizing monoclonal antibodies targeting receptor binding domain (RBD) of SARS-CoV-2-S were obtained. This efficient and reliable pseudovirus assay model could facilitate the development of new drugs and vaccines.</p>
   </div>
   <h3>Competing Interest Statement</h3>
   <p id="p-3">The authors have declared no competing interest.</p>
   <div class="section fn-group" id="fn-group-1">
    <h2>Footnotes</h2>
    <ul>
     <li class="fn-update fn-group-summary-of-updates" id="fn-1">
      <p id="p-4">The last sentence of result "Vero-E6 cells packaged the VSVdG-SARS-CoV-2-Sdel18 with highest efficiency" updated to clarify the virus titer produced by Vero-E6 cell. "The results showed that the Vero-E6 formed more syncytia than the other two cell lines during the packaging, and also produced highest viral titer (Figure 3), which was about 3x105 infectious particles per micro liter. " was replaced with "The results showed that the Vero-E6 formed more syncytia than the other two cell lines during the packaging, and also produced highest viral titer (Figure 3), which was about 3x105 infectious particles per miniliter. "</p>
     </li>
    </ul>
   </div>
   <span class="highwire-journal-article-marker-end"/>
  </div>
 </body>
</html>
